What is the appropriate dose of MiraLAX (polyethylene glycol 3350) for a 2‑year‑old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

MiraLAX Dose for a 2-Year-Old

For a 2-year-old child with functional constipation, start with 0.4 to 0.8 g/kg/day of polyethylene glycol 3350 (PEG 3350), mixed in 4-8 ounces of liquid, given once daily.

Dosing Algorithm

Initial Maintenance Dose

  • Start at 0.4-0.8 g/kg/day (approximately 4-8 grams for an average 10-12 kg toddler) 1, 2
  • Mix the powder in any beverage (4-8 oz of liquid)
  • Give once daily, preferably at the same time each day

Dose Titration

  • Target outcome: 1-2 soft, painless stools per day
  • Adjust dose every 3 days based on response 3
  • Effective maintenance range: Most children respond to 0.7-1.1 g/kg/day 1, 2
  • If diarrhea occurs, reduce the dose rather than stopping treatment

Duration

  • Continue for several months as needed—studies show safety and efficacy for 6-21 months in this age group 1, 2

Evidence Quality and Rationale

The pediatric research evidence for children under 2 years is robust. Two key retrospective studies specifically evaluated PEG 3350 in infants and toddlers under 24 months:

  • Loening-Baucke et al. (2004) found a mean effective dose of 1.1 g/kg/day short-term and 0.8 g/kg/day long-term, with 85% short-term and 91% long-term success 1
  • Michail et al. (2004) reported a mean effective maintenance dose of 0.78 g/kg/day (range 0.26-1.26 g/kg/day), with 97.6% success in children under 18 months 2

A 2008 placebo-controlled trial in older children (mean age 8.5 years) established that 0.4 g/kg/day is the optimal starting dose, with 74% treatment success compared to 42% with placebo 4. While this study didn't include 2-year-olds specifically, it provides the best controlled evidence for initial dosing strategy.

Safety Profile

PEG 3350 is safe and well-tolerated in children under 2 years 5, 1, 2:

  • Common side effects: Transient diarrhea (resolves with dose adjustment), mild abdominal discomfort, increased gas
  • No serious adverse events reported in multiple studies
  • No electrolyte disturbances when using PEG 3350 without electrolytes 6
  • Side effects are dose-dependent and typically resolve by lowering the dose

Important Clinical Considerations

Palatability

  • PEG 3350 is tasteless and grit-free when properly dissolved 7
  • Can be mixed in any beverage, including milk, juice, or water
  • Better acceptance than magnesium hydroxide in children over 4 years, though equally acceptable under 4 years 8

Common Pitfalls to Avoid

  1. Don't stop treatment prematurely: Constipation often requires months of treatment; stopping too early leads to recurrence
  2. Don't discontinue for mild diarrhea: Simply reduce the dose by 25-50% rather than stopping
  3. Don't use fixed adult doses: Always calculate based on weight (g/kg/day), not the standard adult 17g dose
  4. Don't forget behavioral modification: Combine PEG with toilet training and dietary counseling for optimal results 4

When to Adjust Dosing

  • Increase dose if: <3 bowel movements per week, continued hard stools, straining, or pain
  • Decrease dose if: Diarrhea (>3 watery stools/day), excessive loose stools, or abdominal cramping
  • Maximum studied dose: Up to 1.4 g/kg/day has been used safely 3

Practical Prescribing

For a typical 12 kg 2-year-old:

  • Starting dose: 5-10 grams (approximately 1 capful = 17g, so use roughly 1/3 to 1/2 capful)
  • Mix in 4-8 oz of the child's preferred beverage
  • Give once daily
  • Adjust every 3 days to achieve 1-2 soft stools daily

The evidence strongly supports PEG 3350 as first-line therapy for functional constipation in this age group, with a well-established safety profile and high efficacy rates when dosed appropriately 5, 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.